Shingles (Disease)

Eli Lilly said on Tuesday that it would buy three vaccine developers in deals collectively worth up to $4 billion, a move that signals a return to an area that had not been a major focus for the company in recent years. The three are Curevo, a Seattle-area company developing a vaccine against shingles; LimmaTech…